Vol. 3 No. 5 (2023)
Reimbursement Recommendations

Ciltacabtagene Autoleucel (Carvykti)

Published May 17, 2023

Key Messages

  • CADTH recommends that Carvykti should be reimbursed by public drug plans for the treatment of adult patients with multiple myeloma (MM) who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment if certain conditions are met.
  • Carvykti should only be covered to treat patients who have MM; received at least 3 prior treatments including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody; did not respond to their last treatment, and are in relatively good health (i.e., have a good performance status, as determined by a specialist). Carvykti should not be reimbursed to treat patients whose MM is affecting their brain or spinal cord or patients showing signs that the tissue layers protecting the brain and spinal cord are affected by MM. It also should not be reimbursed in patients who have previously received a treatment that targets B-cell maturation antigen.
  • Carvykti should only be reimbursed for patients who have not yet been treated with chimeric antigen receptor (CAR) T-cell therapy, if it is prescribed and administered in a hospital setting with adequate resources by specialists with expertise in MM, and if the cost of Carvykti is reduced.